JANSSEN BIOTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1979-01-01
- Employees
- 10K
- Market Cap
- -
An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis
Active, not recruiting
- Conditions
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Biotech, Inc.
- Target Recruit Count
- 537
- Registration Number
- NCT02808780
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Janssen Biotech, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01962974
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
- First Posted Date
- 2013-04-16
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Janssen Biotech, Inc.
- Registration Number
- NCT01833039
An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2015-07-21
- Lead Sponsor
- Janssen Biotech, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT01555606
A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Janssen Biotech, Inc.
- Target Recruit Count
- 478
- Registration Number
- NCT01550744
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2011-03-14
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Janssen Biotech, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT01314118
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Janssen Biotech, Inc.
- Target Recruit Count
- 297
- Registration Number
- NCT01190839
Golimumab Safety and Surveillance Program Using the Ingenix NHI Database
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Janssen Biotech, Inc.
- Target Recruit Count
- 1064
- Registration Number
- NCT01081717
Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- Janssen Biotech, Inc.
- Target Recruit Count
- 2040
- Registration Number
- NCT01081730
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- Janssen Biotech, Inc.
- Target Recruit Count
- 433
- Registration Number
- NCT01004432
© Copyright 2024. All Rights Reserved by MedPath